The medical device firm forecasts iDose TR sales of $275M-$280M as Q2 2026 revenue surges 50% year-over-year to $185.6 million.
Glaukos set a 2026 net sales target of $680M-$700M, driven by expected iDose TR revenue of $275M-$280M. The outlook follows a record Q2 2026 performance, with consolidated net sales rising 50% to $185.6 million from the prior-year quarter.
The company attributed the growth to strong demand for its glaucoma treatment products. Q2 2026 sales increased 49% on a constant currency basis, reflecting broad market adoption. Management highlighted iDose TR as a key growth driver for the remainder of the year.
No immediate market reaction was disclosed in the earnings call summary.